

WHAT'S NEW WITH THE FLU?

Mark H. Sawyer MD

UCSD School of Medicine/Rady Children's Hospital San Diego

San Diego Immunization Partnership







DISCLOSURES




- I have no financial disclosures to make related to this presentation
- My family and I are fully immunized
- I get my flu shot on October 31

OBJECTIVES



- Explain why influenza vaccine is especially important this year so that you promote it aggressively
- List the new things in this year's CDC Influenza recommendations so that you can use the vaccines correctly
- Explain who is NOT getting an influenza vaccine so that you are on the lookout for them

SIBLINGS







Influenza	Sars-CoV-2/COVID
Respiratory virus spread by droplets	Respiratory virus spread by droplets and aerosols
Most infected people don't get severely ill	Most infected people don't get severely ill and many don't have any symptoms at all
Occurs primarily in the winter	Occurs year-round
Causes 12-60,000 deaths in the US every year	So far has caused >1 million deaths in the U.S.
Can be treated with antiviral medications	Can be treated with antiviral medications and monoclonal antibodies
We have several vaccines with 40-60% effectiveness. More effective for prevention of severe disease.	We have several vaccines with 60-85% effectiveness. More effective for prevention of severe disease.
We vaccinate everyone 6 months and older	We vaccinate everyone 6 months and older
About 30% of people don't get vaccinated	About 30% of people haven't gotten fully vaccinated

HIGHLIGHTS FOR 2022-2023




- All Influenza vaccines are now quadrivalent containing 2 influenza A strains and 2 influenza B strains
- This year's vaccine is different than last years with changes to the influenza A (H3N2) and influenza B/Victoria components
- ccIIV4 (cell culture-based vaccine) can now be used down to the age of 6 months giving us 5
 different products in this age group
- Coadministration of influenza vaccine with other vaccines, including COVID vaccine, allowed but there are some guidelines
- Don't immunize in July or August except for pregnant women in their 3rd trimester of pregnancy and children under 9 getting their first of two doses

NOW IS THE TIME-IT'S INFLUENZA VACCINE SEASON







INFLUENZA VACCINE IN THE COVID ERA





More important than ever

- So we don't overburden the healthcare resources
- Because symptoms of influenza are identical with those of COVID so you will run the risk of quarantine if you get influenza
- Because co-infection with influenza and Sars-CoV-2 is possible and may be very severe


May be challenging to give along with COVID vaccine

- Multiple vaccination events
- Tracking which vaccines have been given

Difficult to judge demand

Hopefully demand will be high for the reasons above

INFLUENZA VIRUS NOMENCLATURE



^{1.} CDC. Atkinson W, et al. Chapter 13: Influenza. In: Epidemiology and Prevention of Vaccine-Preventable Diseases, 4th ed. Department of Health and Human Services, Public Health Service, 1998, 220

VARIATION IN INFLUENZA VACCINE EFFECTIVENESS



Table. Adjusted vaccine effectiveness estimates for influenza seasons from 2005-2016

Influenza Season'	Reference	Study Site(s)	No. of Patients	Adjusted Overall VE (%)	95% CI
2004-05	Belongia 2009	WI	762	10	-36, 40
2005-06	Belongia 2009	WI	346	21	-52, 59
2006-07	Belongia 2009	WI	871	52	22 ,70
2007-08	Belongia 2011	WI	1914	37	22, 49
2009-10	Griffin 2011	WI, MI, NY, TN	6757	56	23, 75
2010-11	Treanor 2011	WI, MI, NY, TN	4757	60	53, 66
2011-12	Ohmit 2014	WI, MI, PA, TX, WA	4771	47	36, 56
2012-13	McLean 2014	WI, MI, PA, TX, WA	6452	49	43, 55
2013-14	Unpublished	WI, MI, PA, TX, WA	5990	51	43, 58
2014-15	ACIP presentation, Flannery	WI, MI, PA, TX, WA	9329	23	14, 31
2015-16*	ACIP presentation, Flannery	WI, MI, PA, TX, WA	7563	47*	39, 53*

https://www.cdc.gov/flu/prof essionals/vaccination/effectiv eness-studies.htm

UPDATE FOR 2021-2022 EFFECTIVENESS FOR WHAT?



- The 2021-2022 influenza vaccine was 34-44%
 effective for prevention of an illness that brings
 you to the clinic and you need an influenza test
- More effective for preventing hospitalization
- Even more effective for preventing death





Can you give the influenza vaccine too early?

WANING INFLUENZA VACCINE EFFECTIVENESS



Table 4. Summary of Findings

				VE (95% CI), by Time After Vaccination		
Outcome	Participants, No. (Studies)	Studies, No.	Evidence Certainty ^a	ΔVE (95% CI)	15–90 d	91–180 d
Influenza A(H3)	10 736 cases, 27 689 controls	11	Moderate	-33 (-57 to -12)	45 (34 to 54)	13 (-10 to 31)
Influenza B	6424 cases, 17 877 controls	6	Low	-19 (-33 to -6)	62 (52 to 70)	43 (33 to 52)
Influenza A(H1)	5148 cases, 17 044 controls	5	Low	-8 (-27 to 21)	62 (35 to 78)	54 (43 to 63)

Aggregate odds ratios from the meta-analysis in Figure 2 were converted to VE values, stratified by influenza virus type/subtype and time since vaccination, with bootstrapped estimates used for ΔVE.

Abbreviations: CI, confidence interval; VE, vaccine effectiveness.

^aBased on the Grading of Recommendations Assessment, Development and Evaluation.

WHEN TO GIVE INFLUENZA VACCINE



- The goal is to immunize everyone by November 1
- Immunize children who need 2 doses of vaccine and pregnant women in their 3rd trimester of pregnancy as soon as you can
- Immunize anyone who may not be back/come back as soon as you can
- Otherwise wait until September
- No recommendation for a second dose half-way through the season

INFLUENZA-WHO DO WE WORRY ABOUT THE MOST?



HIGH RISK CONDITIONS

- Children under 5 years
- Pregnant women
- Adults over 50 years
- Everyone with chronic lung, heart, kidney, liver, neurologic diseases
- Residents of long-term care facilities
- Immunocompromised people
- American Indian/Alaskan Natives
- Persons with extreme obesity
- Children on chronic aspirin

WHO ELSE IS VERY IMPORTANT TO IMMUNIZE?



- People who care for the high-risk groups
 - Household contacts
 - Other caregivers
- Health care personnel









Trade name (manufacturer)	Presentations	Age indication	μg HA (IIV4s and RIV4) or virus count (LAIV4) for each vaccine virus (per dose)	Route	Mercury (from thimerosal, if present) μg/0.5 mL
IIV4 (standard-dose, egg-based vaco	cines†)				
Afluria Quadrivalent	0.5-mL PFS [§]	≥3 yrs [§]	15 µg/0.5 mL	IM [¶]	**
(Seqirus)	5.0-mL MDV [§]	≥6 mos [§]	$7.5 \mu \text{g}/0.25 \text{mL}$	IM [¶]	24.5
		(needle and syringe)	15 μg/0.5 mL		
		18 through 64 yrs			
		(jet injector)		_	
Fluarix Quadrivalent (GlaxoSmithKline)	0.5-mL PFS	≥6 mos	15 μg/0.5 mL	IM¶	_
FluLaval Quadrivalent (GlaxoSmithKline)	0.5-mL PFS	≥6 mos	15 μg/0.5 mL	IM¶	_
Fluzone Quadrivalent	0.5-mL PFS ^{††}	≥6 mos ^{††}	15 μg/0.5 mL	IM [¶]	_
(Sanofi Pasteur)	0.5-mL SDV ^{††}	≥6 mos ^{††}	15 μg/0.5 mL	IM [¶]	_
	5.0-mL MDV ^{††}	≥6 mos ^{††}	7.5 μg/0.25 mL 15 μg/0.5 mL	IM¶	25



TABLE 1. Influenza vaccines — United States, 2022–23 influenza season*

Trade name (manufacturer)	Presentations	Age indication	μg HA (IIV4s and RIV4) or virus count (LAIV4) for each vaccine virus (per dose)	Route	Mercury (from thimerosal, if present), μg/0.5 mL
cellV4 (standard does cell culture	hasad vassina)				
ccIIV4 (standard-dose, cell culture-	•		15 /0 5		
Flucelvax Quadrivalent	0.5-mL PFS	≥6 mos	15 μg/0.5 mL	IM¶	_
(Seqirus)	5.0-mL MDV	≥6 mos	15 μg/0.5 mL	IM¶	25
HD-IIV4 (high-dose, egg-based vacc	cine [†])				
Fluzone High-Dose Quadrivalent (Sanofi Pasteur)	0.7-mL PFS	≥65 yrs	60 μg/0.7 mL	IM¶	_
allV4 (standard-dose, egg-based va	ccine [†] with MF59 adjuvant)				
Fluad Quadrivalent (Segirus)	0.5-mL PFS	≥65 yrs	15 μg/0.5 mL	IM¶	_
RIV4 (recombinant HA vaccine)					
Flublok Quadrivalent (Sanofi Pasteur)	0.5-mL PFS	≥18 yrs	45 μg/0.5 mL	IM¶	_
LAIV4 (egg-based vaccine†)					
FluMist Quadrivalent	0.2-mL prefilled single-	2 through 49 yrs	10 ^{6.5–7.5} fluorescent	NAS	_
(AstraZeneca)	use intranasal sprayer		focus units/0.2 mL		

UPDATE VACCINES FOR OLDER (>65 YEARS) ADULTS



- High dose IIV4 (HD-IIV4)
- Recombinant IIV4 (RIV)
- Adjuvanted IIV4 (aIIV4)

- Probably all work better than other IIV vaccines
 - HD-IIV3 24% more effective
 - RIV 17-30% more effective
 - allV3 ??63% more effective

Now preferred for adults 65 years and older when available

PEDIATRIC DOSING-BE CAREFUL



TABLE 4. Dose volumes for inactivated influenza vaccines approved for children aged 6 through 35 months* — United States, 2022–23 influenza season

Trade name (Manufacturer)	Dose volume for children aged 6 through 35 mos (µg HA per vaccine virus)
Afluria Quadrivalent (Segirus)	0.25 mL (7.5 μg) [†]
Fluarix Quadrivalent (GlaxoSmithKline)	0.5 mL (15 μg)
Flucelvax Quadrivalent (Segirus)	0.5 mL (15 μg)
FluLaval Quadrivalent (GlaxoSmithKline)	0.5 mL (15 μg)
Fluzone Quadrivalent (Sanofi Pasteur)	0.5 mL (15 μg) [§]

ALLERGIES



TABLE 3. Influenza vaccine contraindications and precautions for persons with a history of severe allergic reaction to a previous dose of an influenza vaccine* — United States, 2022–23 influenza season


Vaccine (of any valency) associated with	Available 2022–23 influenza vaccines				
previous severe allergic reaction (e.g., anaphylaxis)	Egg-based IIV4s and LAIV4	ccIIV4	RIV4		
Any egg-based IIV or LAIV	Contraindication [†]	Precaution [§]	Precaution [§]		
Any ccllV	Contraindication [†]	Contraindication [†]	Precaution [§]		
Any RIV	Contraindication [†]	Precaution [§]	Contraindication [†]		
Unknown influenza vaccine	Allergist consultation recommended				

If you are allergic to eggs, you can get any influenza vaccine!

TWO DOSES OF INFLUENZA VACCINE FOR YOUNG CHILDREN-UPDATE



FIGURE. Influenza vaccine dosing algorithm for children aged 6 months through 8 years* — Advisory Committee on Immunization Practices, United States, 2022–23 influenza season



* Children aged 6 months through 8 years who require 2 doses of influenza vaccine should receive their first dose as soon as possible (including during July and August, if vaccine is available) to allow the second dose (which must be administered ≥4 weeks later) to be received, ideally, by the end of October. For children aged 8 years who require 2 doses of vaccine, both doses should be administered even if the child turns age 9 years between receipt of dose 1 and dose 2.

One dose of vaccine in this population provides very little protection!

MMWR, August 26, 2022 71(1):1-28

COADMINISTRATION



- OK to give COVID vaccine and influenza, or any other vaccine, at the same visit
- Some concern about cumulative adverse events, particularly with the adjuvanted influenza vaccine and other vaccine with non-aluminum based adjuvants (adjuvanted hepatitis B vaccine, adjuvanted zoster vaccine). Should at least give in opposite arms
- OK to give live virus vaccines on the same day (e.g. LAIV and MMR)
- If not given on the same day you should have 4 weeks between LAIV and other live virus vaccines (MMR, varicella)

WHO SHOULD GET A FLU VACCINE?



Everyone 6 months of age and older!














INFLUENZA VACCINE COVERAGE-CHILDREN






2010–2011 2010–2011 2012–2013 2013–2014 2014–2015 2015–2016 2016–2017 2017–2018 2018–2019 2019–2020 Influenza Season

Pediatrics 2021;148(4):e2021053745

UPDATE INFLUENZA VACCINE COVERAGE -ADULTS







https://www.cdc.gov/flu/fluvaxview/interactive-general-population.htm

WHERE TO GO FOR MORE INFORMATION



San Diego HHSA Immunization Branch (SDIZ.org)

California Department of Public Health (www.cdph.ca.gov)

CDC (cdc.gov/vaccines)



- Lots of similarities between influenza and COVID
- Influenza vaccine is more important than ever
- We have work to do to immunize everyone
- Special products now preferred for those 65 years and older.
- Pay attention to dosing for young children
- Get your influenza vaccine this year!